Non-executive appointment

Ardana PLC
17 June 2005



                       ARDANA APPOINTS NEW NON-EXECUTIVE
                                  TO THE BOARD

Edinburgh, UK, 17 June 2005; Ardana, the emerging pharmaceutical company focused
on improving human reproductive health, today announces that

Carol Ferguson has been appointed as a non-executive director and as Chair of
the audit committee.


From 1990-1996 Mrs Ferguson was Finance Director of Timney Fowler Ltd, a textile
design company. Prior to this she was a financial journalist and columnist for
The Times drawing on her 14 years experience in investment, fund management,
research and sales. Between 1977-1987, she headed up the oil department at
stockbrokers Wood Mackenzie & Co in Edinburgh and was ranked No 1 oil analyst by
Extel for six successive years.


Since leaving Timney Fowler, Mrs Ferguson has been involved with several public,
private and voluntary organisations in a non-executive or advisory capacity,
primarily chairing audit committees. In 2002, she was elected a member of the
executive committee of the Association of Investment Trust Companies and was
recently appointed a Deputy Chairman. Current non-executive appointments include
Monks IT, Gartmore Smaller Companies IT, Merrill Lynch Greater Europe IT and
Vernalis plc.


Maureen Lindsay, CEO of Ardana, said:


'Carol brings considerable financial expertise to our Board and we are delighted
that she is joining us.  She has an impressive background and her current
directorships demonstrate how highly she is valued in an advisory capacity. Her
contributions will be invaluable as we take our product pipeline closer to
commercialisation.'



For more information contact:


Ardana                                   Financial Dynamics
Maureen Lindsay                          (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550               Julia Phillips/Davina Langdale
                                         Tel: [phone]


                                          NB Public Relations
                                          (trade/technical media relations)
                                          Nicki Brimicombe
                                          Tel: + 44 (0)1883 732353



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
outlicensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



  • StriantTM SR, a testosterone replacement therapy that has already been
    launched by Ardana through its own sales force in the UK as a treatment for
    men with hypogonadism and for which Ardana has marketing rights in Europe;
  • Teverelix LA, in development for three initial indications (prostate
    cancer, BPH and endometriosis);
  • Testo Bi-gel, a trans dermal testosterone delivery system in development
    for the treatment of male hypogonadism, shortly to enter Phase II trials;
  • Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.





In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana completed its IPO on the London Stock Exchange in March 2005 raising £21
million.



For further information please see www.ardana.co.uk










                      This information is provided by RNS
            The company news service from the London Stock Exchange